The advent of small-molecule targeted therapies, a decade ago, revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite a remarkable initial response that can be seen in a majority of patients, most of them will undergo relapse even after spectacular initial responses. These relapses are due to ‘dormant’ persistent cells, unresponsive to treatment.
Click here for original story, Awakening ‘dormant’ cells to fight cancer
Source: ScienceDaily